Cell Count, Viability, and Documentation: What Patients Should Demand Before a Procedure

One of the most significant gaps in how regenerative medicine is discussed publicly is the near-total silence around what actually gets measured before a stem cell injection takes place. Patients research the therapy, consult with clinics, and often receive detailed explanations of what stem cells do in the body. What they rarely receive is a straightforward answer to a more fundamental question: how many live cells are in the preparation that will be injected, and how was that verified? This article explains what cell count and viability mean, why they matter clinically, why many clinics do not provide this documentation, and what patients are reasonable to ask for before any stem cell procedure.

What Cell Count Means in Regenerative Medicine

Why the Number of Cells Delivered Is Clinically Relevant

In pharmaceutical medicine, dose is one of the most rigorously controlled variables. Drug concentrations are standardized, measured, and labeled. The patient and the prescribing physician know precisely what is being administered.

Cell therapy presents a different challenge, but the fundamental principle is the same. The number of cells delivered to a treatment site is a variable that affects what that treatment may or may not do. Research suggests a dose-response relationship exists in stem cell therapy, though the precise optimal dose for any given condition has not been fully established across the literature.

What is well established is that delivering a subtherapeutic number of cells may produce little or no biological effect. Mesenchymal stem cells (MSCs) exert their effects primarily through paracrine signaling, meaning they release growth factors and cytokines that modulate the surrounding tissue environment. A very small number of cells cannot produce sufficient signal to meaningfully influence a joint or tissue environment. Published dosing ranges in regenerative medicine literature for orthopedic applications typically describe therapeutic targets in the range of tens of millions of cells, though protocols vary.

The cell count is not sufficient on its own, because a count that includes both living and dead cells overstates the functional dose. But it is a necessary starting point. A patient receiving a preparation described as containing “stem cells” without any documentation of how many is in the same position as a patient receiving a medication with no dosage label.

How Cell Count Is Measured

Several methods exist for counting cells in a prepared sample. The hemocytometer is a traditional glass slide chamber with a grid etched into its surface. A small volume of the cell suspension is placed under a coverslip, and the cells visible in defined grid squares are counted under a microscope. The cell density of the full sample is then calculated from this count. Hemocytometry is accurate in experienced hands but is labor-intensive and introduces inter-operator variability.

Automated cell counting systems, sometimes called automated counters or Coulter-principle counters, use electrical impedance or light scattering to count particles in a sample at high speed and with high reproducibility. These systems are more objective than manual hemocytometry and generate an electronic record of the count, which is important for documentation purposes.

Flow cytometry is the most detailed method for cell characterization. It can count cells, assess their size and granularity, and simultaneously detect specific surface proteins that identify cell populations. For clinical MSC preparations, flow cytometry can confirm that the cells being counted are in fact the intended cell type (based on surface markers) and not contaminants or non-target cells. This level of analysis goes beyond simple counting and provides information about cell identity and population purity.

The laboratory report generated from any of these methods should include the total cell count (typically expressed in millions per milliliter), the method used to generate the count, the date and time the analysis was performed, and the identity of the technician responsible.

What Cell Viability Means

Live vs. Dead Cells: Why the Ratio Matters

A cell count without a viability assessment is incomplete information. It tells you how many particles are present but not how many of them are alive and capable of biological activity.

Dead cells do not signal repair. They do not release paracrine factors, they do not home to injury sites, and they do not interact with the tissue environment in any therapeutically relevant way. Injecting a preparation in which a large percentage of cells are dead is not equivalent to injecting the same volume of living cells.

Beyond being therapeutically inactive, dead cells may contribute to an inflammatory response. When cells die, particularly through necrotic pathways, they release intracellular contents that can trigger immune activation. Introducing high proportions of dead cells into a joint or tissue may, in some contexts, provoke inflammatory signaling rather than the repair-supportive signaling that the therapy intends to create.

This is why viability thresholds matter in clinical practice. Research and regulatory guidance in the cell therapy field commonly reference minimum viability thresholds. Clinical standards from organizations including FACT and AABB reference viability testing requirements for cell therapeutic products. Many practitioners working in regenerative medicine cite 80 percent or higher as a minimum acceptable viability for injection, with higher targets preferred. Some advanced processing protocols document viability of 95 percent or higher at the time of release.

What causes viability to fall? Temperature excursions during storage or handling are a primary cause. Cell suspensions exposed to temperatures outside the appropriate range, whether too warm or too cold, experience accelerated cell death. Research confirms that stem cell viability is sensitive to temperature conditions: cells stored at 4 degrees Celsius maintain viability substantially better over time than cells held at room temperature, and brief exposures to 37 degrees Celsius accelerate deterioration significantly. Time outside appropriate conditions also matters. The longer cells are held before injection, the more viability diminishes without active monitoring and environmental control.

Transport is another common cause of viability loss. Cells packaged for courier delivery to an external lab, or processed cells returned to a clinic after external processing, experience handling, temperature variation, and time delays that collectively reduce viability before injection.

How Viability Is Tested Before a Procedure

The most widely used viability test is the trypan blue exclusion assay. Trypan blue is a dye that crosses the compromised membrane of dead cells and stains them blue, while live cells with intact membranes exclude the dye and remain clear. Under a microscope, the proportion of clear cells (living) to blue cells (dead) provides the viability percentage.

Trypan blue exclusion is simple, inexpensive, and fast, which is why it remains common in clinical settings. Research does note limitations: manual trypan blue counting introduces operator subjectivity, and the method becomes less accurate at viabilities below 70 percent, where it tends to overestimate the proportion of living cells. Published research recommends using trypan blue primarily for samples expected to have high viability (above 70 percent), and using flow cytometry-based methods for more complex or lower-viability samples.

Flow cytometry using viability dyes such as propidium iodide (PI) or 7-aminoactinomycin D (7-AAD) provides a more objective and detailed viability assessment. These dyes enter cells with compromised membranes and bind nucleic acids, generating a fluorescent signal detected by the instrument. Flow cytometry generates a digital record, allows simultaneous analysis of cell type and viability in the same run, and is not subject to the same operator subjectivity as manual microscopy.

The critical point about timing is that viability testing must happen before the injection, not after. Testing a sample after it has been injected tells the patient nothing useful. The clinically meaningful verification is the viability at the time the preparation is ready for use. This is why same-day processing and testing in an in-house laboratory changes the quality picture in meaningful ways.

Why Most Clinics Don’t Provide This Documentation

External Lab Processing and the Documentation Gap

When a clinic sends patient tissue to an external processing laboratory, the chain of information becomes fractured. The external lab receives the tissue, processes it according to their protocol, performs quality checks according to their internal procedures, and returns the processed cells. What the clinic receives is a product. What documentation accompanies that product, and how much of it makes its way to the patient, varies.

Some external labs provide a processing report. Some of that documentation is retained by the external lab and not shared with the clinic, or shared in a format that the clinic does not pass on to the patient. In some cases, cells are returned to the clinic and injected based on the external lab’s internal quality review, which the patient has no direct access to and which the clinic’s physician may not have reviewed in detail.

Cost and operational logistics also factor into the documentation gap. Generating detailed quality reports takes time and adds cost. Some clinics accept the processed product on trust and proceed to injection without independently verifying the quality of what they received. The patient, who has no visibility into this sequence, receives an injection of cells whose count and viability they have no documentation for.

What Happens When Viability Is Never Verified

When a patient receives a stem cell injection without any verification of cell count or viability, several meaningful quality assurances are absent. The patient cannot know whether the cell dose delivered was within the range that research suggests is therapeutically relevant. The patient cannot know what proportion of cells in the injection were alive. The patient has no documented baseline for comparing the results of subsequent procedures or for evaluating whether the treatment provided adequate biological material.

If the procedure does not produce the hoped-for response, the cause is opaque. It may be that the patient’s condition did not respond to the therapy. Or it may be that the cell preparation had inadequate count, low viability, or both. Without documentation, no one can determine which factor was responsible, and no evidence-based adjustment to the protocol is possible.

This documentation gap also has accountability implications. Transparent documentation of what was delivered creates a record. Without it, claims about the quality of the treatment are assertions rather than verifiable facts.

What Patients Should Ask For

The Specific Report to Request Before Your Procedure

Before proceeding with any stem cell procedure, patients are in a reasonable position to ask the treating clinic for their cell count and viability report. A specific, straightforward way to make this request is: “I would like to see the cell count and viability report for my sample before we proceed.”

A legitimate, verifiable report should contain several specific pieces of information. The total cell count expressed in measurable units, typically millions of cells per milliliter, should be present. The viability percentage should be documented, not estimated. The date and time the testing was performed should appear on the report, because this establishes whether the testing reflects the product as it exists at the time of injection. The method used, whether trypan blue exclusion, automated counting, or flow cytometry, should be identified. The name or identifier of the technician responsible for the analysis is an important accountability element.

Additionally, patients are reasonable to ask whether the processing and testing happened in-house or at an external laboratory. This context changes what the documentation chain looks like and whether the treating physician has direct access to verify the results.

How to Interpret What You Receive

Cell count is typically reported in millions of cells. Understanding whether the count delivered is in a clinically meaningful range for the condition being treated requires a conversation with the physician. Patients can ask the physician directly: “What cell count are you targeting for my treatment, and does the report confirm we are within that range?”

Viability is a percentage. A viability of 90 percent means approximately nine out of ten cells in the preparation are alive. A viability of 60 percent means four out of ten are dead before injection. Published guidance in regenerative medicine commonly places the minimum acceptable threshold at 80 percent, with higher being preferable.

Red flags in a viability report include a percentage below 70 percent, which falls below what most cell therapy standards consider acceptable. A report with no date or time of testing raises the question of when the viability was measured and whether it reflects the product at the time of injection. A report with no identified testing method is not verifiable. A cell count below published therapeutic ranges for the condition being treated warrants direct conversation with the physician about whether the yield is sufficient to proceed.

Patients who receive answers like “we don’t provide that documentation” or “trust the process” in response to these questions are encountering a quality transparency gap that is worth taking seriously before proceeding.

What Transparent Clinics Do Differently

Clinics with in-house laboratories and a commitment to quality transparency operate differently from clinics that outsource processing without patient documentation. In a transparent in-house model, the laboratory generates the cell count and viability report as a standard step in processing on the day of the procedure. The treating physician reviews the results before the patient enters the procedure room.

If the results meet quality thresholds, the procedure proceeds as planned. If for any reason the yield is lower than expected or viability falls below the target range, the physician has the information needed to make a clinical decision in real time: whether to harvest additional material, reschedule the procedure, modify the protocol, or have a transparent conversation with the patient about the situation.

The patient receives documentation as a matter of course, not as a special request. This documentation becomes part of their clinical record and can be used to compare results across procedures, provide information to other treating physicians, and serve as a verifiable record of what they received. This is the standard that patients seeking high-quality autologous stem cell therapy are reasonable to expect, and it is the standard that an in-house laboratory approach is designed to meet.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.